Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2007-03-20
2007-03-20
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S133100, C424S138100, C424S141100, C424S143100, C424S144100, C424S155100, C424S173100, C530S387100, C530S387300, C530S387700, C530S388100, C530S388200, C530S388220, C530S388700, C530S388730
Reexamination Certificate
active
11139499
ABSTRACT:
The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (GD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.
REFERENCES:
patent: 4816397 (1989-03-01), Boss
patent: 4816567 (1989-03-01), Cabilly
patent: 5116964 (1992-05-01), Capon
patent: 5304635 (1994-04-01), Imam
patent: 5434131 (1995-07-01), Linsley
patent: 5521288 (1996-05-01), Linsley
patent: 5580756 (1996-12-01), Linsley
patent: 5747034 (1998-05-01), De Boer
patent: 5770197 (1998-06-01), Linsley
patent: 5844095 (1998-12-01), Linsley
patent: 5885579 (1999-03-01), Linsley
patent: 6051228 (2000-04-01), Aruffo
patent: 6113898 (2000-09-01), Anderson
patent: 6162432 (2000-12-01), Wallner
patent: 6709654 (2004-03-01), Anderson et al.
patent: 6893638 (2005-05-01), Anderson et al.
patent: 0 173 494 (1986-03-01), None
patent: 0 194 276 (1986-03-01), None
patent: 0 451 216 (1991-10-01), None
patent: 0 171 496 (1993-05-01), None
patent: 0 555 880 (1993-08-01), None
patent: 0 555 880 (1993-08-01), None
patent: 0 239 400 (1994-08-01), None
patent: 0 682 040 (1995-11-01), None
patent: 2 177 096 (1986-03-01), None
patent: WO 87/01131 (1987-02-01), None
patent: WO 92/06193 (1992-04-01), None
patent: WO 93/02108 (1993-02-01), None
patent: WO 93/09812 (1993-05-01), None
patent: WO 94/28912 (1994-12-01), None
patent: WO 95/06481 (1995-03-01), None
patent: WO 95/06666 (1995-03-01), None
patent: WO 95/22619 (1995-08-01), None
patent: WO 95/33770 (1995-12-01), None
patent: WO 96/40878 (1996-12-01), None
patent: WO 98/19706 (1998-05-01), None
Freeman et al., “Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7,”J. Exp. Med., 1991, 174(3):625-631.
Hathcock et al., J. Exp. Med. 180:631-640 (1994).
Alegre M., et al, “Effect of single amino acid mutation on the activating and immunosuppressive properties of a “Humanized” OKT3 monoclonal antibody,” J. Immunol., 1992, 148:3461-3468.
Armitage R.J., et al., “Molecular and biologial characterization of a murine ligand for CD40,” Nature, 1992, 357:80-82.
Azuma M., et al., “CD28 Interaction with B7 Costimulates Primary Allogeneic Proliferative Responses and Cytotoxicity Mediated by Small Resting T Lymphocytes,” J. Exp. Med., 1992, 175:353-360.
Azuma.M., et al., “Functional Expression of B7/BB1 on Activated T Lymphocytes,” J. Exp. Med., 1993, 177:845-850.
Azuma M.D., et al., “B70 Antigen is a Second Ligand for CTLA-4 and CD28,” Nature, 1993, 366:76-79.
Ben-Nun A., et al., “The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis,” Eur J. Immunol., 1981, 11:195-199.
Blazar B.R., et al., “Infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells,” J Immunol., 1996, 157:3250-3259.
Boussiotis V.A., et al., “Activated human B lymphocytes express three CTLA-4 counter-receptors that co-stimulate T-Cell activation,” Proc. Natl. Acad. Sci., USA, 1993,90:11059-11063.
Capon D.J., et al., “Designing CD4 immunoadhesins for AIDS therapy,” Nature, 1989, 337, 525-531.
Cohen J., “New protein steals the show as ‘costimulator’ of T cells,” Science, 1993, 262:844-845.
Cohen J., “Mounting a targeted strike on unwanted immune responses,” (news; comment), Science, 1992, 257:751.
Daikh et al., The CD28-B7 costimulatory pathway and its role in autoimmune disease,J Leukoc Biol62:156-62 (1997).
Dautigny A., et al., “Molecular cloning and nucleotide sequence of a cDNA clone coding for rat brain myelin proteolipid,” FEBS Lett., 1985, 188(1):33-36.
De Boer M., et al., “Functional Characterization of a Novel Anti-B7 Monoclonal Antibody,” Eur. Journal of Immunology, 1992, 22:3071-3075.
Delabie J., et al., “The B7/BB1 antigen is expressed by Reed-Stemberg cells of Hodgkin's disease and contributes to the stimulating capacity of Hodgkin's disease-derived cell lines,” Blood, 1993, 82:2845-52.
Dermer G.B., et al., “Another Anniversary for the war on cancer,” Biotechnology, 1994, 12:320.
Dillman R.O., et al., “Antibodies as cytotoxic therapy,” 1994, J Clin Oncol., 12:1497-1515.
Durie F.H., et al., “The role of CD40 and its ligand (gp39) in peripheral and central tolerance and its contribution to autoimmune disease,” Research in Immunology, 1994, 145(3), 200-205 & 244-249.
Durie F.H., et al., “Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40,” Science, 1993, 261:1328-1330.
Engel et al, “The B7-2(B70) costimulatory molecule expressed by monocytes and activted B lymphocytes is the CD86 differentiation antigen,” Blood, 1994, 84, 1402-1407.
Falini B., et al., “Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin,” The Lancet, 1992, 339:1195-1196.
Freeman G.J., et al., “Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice,” Science, 1993, 262:907-909.
Freeman G.J., et al., “CTLA-4 and CD28 MRNA are Coexpressed in Most T Cells After Activation,” J Immunol, 1992, 149:3795-3801.
Freeman G.J., et al., “Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation,” Science, 1993, 262:909-911.
Geenen V. and G. Kroemer, “Multiple Ways to Cellular Immune Tolerance,” Immunology Today, 1993, 14:573.
Gerritse K., et al., “CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis,” Proc. Natl. Acad. Sci. USA, 1996, 93:2499-2504.
Gimmi C.D., et al., “Human T-Cell Clonal Anergy is Induced by Antigen Presentation in the Absence of B7 Costimulation,” Proc. Natl. Acad. Sci., 1993, 90:6586-6590.
Gottlieb A., et al., “Results of a single-dose, dose-escalating trial of an anti-B7.1 monoclonal antibody (IDEC-114) in patients with psoriasis,” J Invest Dermatol., 2000, 114:840, Abstract No. 546.
Gottlieb A., et al., “Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibody,” J Am Acad Dermatol., 2002, 47:692-700.
Gribben J.G., et al., “CTLA-4 mediates antigen specific apoptosis of human T cells.” Proc. Natl. Acad. Sci. USA, 1995, 92:811-815.
Grumet F.C., et al., “Soluble form of an HLA-B7 Class I Antigen Specifically Suppresses Humoral Alloimmunization.” Human Immunology, 1995, 40:228-234.
Guinan E.C., et al., “Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity,” Blood, 1994, 84:3261-3282.
Hafler D.A., et al., “The potential of restricted T cell recognition of myelin basis protein epitopes in the therapy of multiple sclerosis,” Ann. NY Acad. Sci., 1991, 636:251-265.
Harding F.A., et al., “CD28 Mediated Signalling Co-stimulates Murine T Cells and Prevents Induction of Anergy in T Cell Clones.” Nature, 1992, 356:607-609.
Hariharan K., et al., “Therapeutic activity of IDEC-114 (anti-CD80) and rituximab (Rituxa
Anderson Darrell R.
Brams Peter
Hanna Nabil
Biogen Idec Inc.
Gambel Phillip
Pillsbury Winthrop Shaw & Pittman LLP
LandOfFree
CD80 specific antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with CD80 specific antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CD80 specific antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3788074